243 related articles for article (PubMed ID: 35201439)
1. Tamoxifen and oxidative stress: an overlooked connection.
Ahmed NS; Samec M; Liskova A; Kubatka P; Saso L
Discov Oncol; 2021 May; 12(1):17. PubMed ID: 35201439
[TBL] [Abstract][Full Text] [Related]
2. The St. Gallen Prize Lecture 2011: evolution of long-term adjuvant anti-hormone therapy: consequences and opportunities.
Jordan VC; Obiorah I; Fan P; Kim HR; Ariazi E; Cunliffe H; Brauch H
Breast; 2011 Oct; 20 Suppl 3(Suppl 3):S1-11. PubMed ID: 22015273
[TBL] [Abstract][Full Text] [Related]
3. Treatment of Postmenopausal Breast Cancer with Selective Estrogen Receptor Modulators (SERMs).
Lewis-Wambi JS; Jordan VC
Breast Dis; 2005-2006; 24():93-105. PubMed ID: 16917142
[TBL] [Abstract][Full Text] [Related]
4. Therapeutic effect of tamoxifen related to estrogen receptor level.
Rose C; Thorpe SM; Løber J; Daenfeldt JL; Palshof T; Mouridsen HT
Recent Results Cancer Res; 1980; 71():134-41. PubMed ID: 6988911
[TBL] [Abstract][Full Text] [Related]
5. Faslodex (ICI 182, 780), a novel estrogen receptor downregulator--future possibilities in breast cancer.
Robertson JF
J Steroid Biochem Mol Biol; 2001 Dec; 79(1-5):209-12. PubMed ID: 11850227
[TBL] [Abstract][Full Text] [Related]
6. Role of estrogen receptor alpha transcriptional coregulators in tamoxifen resistance in breast cancer.
Girault I; Bièche I; Lidereau R
Maturitas; 2006 Jul; 54(4):342-51. PubMed ID: 16822624
[TBL] [Abstract][Full Text] [Related]
7. Reversal of ER-β silencing by chromatin modifying agents overrides acquired tamoxifen resistance.
Pitta CA; Papageorgis P; Charalambous C; Constantinou AI
Cancer Lett; 2013 Sep; 337(2):167-76. PubMed ID: 23752064
[TBL] [Abstract][Full Text] [Related]
8. Combined histone deacetylase inhibition and tamoxifen induces apoptosis in tamoxifen-resistant breast cancer models, by reversing Bcl-2 overexpression.
Raha P; Thomas S; Thurn KT; Park J; Munster PN
Breast Cancer Res; 2015 Feb; 17(1):26. PubMed ID: 25848915
[TBL] [Abstract][Full Text] [Related]
9. Reactivation of cAMP Pathway by PDE4D Inhibition Represents a Novel Druggable Axis for Overcoming Tamoxifen Resistance in ER-positive Breast Cancer.
Mishra RR; Belder N; Ansari SA; Kayhan M; Bal H; Raza U; Ersan PG; Tokat ÜM; Eyüpoğlu E; Saatci Ö; Jandaghi P; Wiemann S; Üner A; Cekic C; Riazalhosseini Y; Şahin Ö
Clin Cancer Res; 2018 Apr; 24(8):1987-2001. PubMed ID: 29386221
[No Abstract] [Full Text] [Related]
10. CB1 and CB2 receptors are novel molecular targets for Tamoxifen and 4OH-Tamoxifen.
Prather PL; FrancisDevaraj F; Dates CR; Greer AK; Bratton SM; Ford BM; Franks LN; Radominska-Pandya A
Biochem Biophys Res Commun; 2013 Nov; 441(2):339-43. PubMed ID: 24148245
[TBL] [Abstract][Full Text] [Related]
11. Identification of GDC-0810 (ARN-810), an Orally Bioavailable Selective Estrogen Receptor Degrader (SERD) that Demonstrates Robust Activity in Tamoxifen-Resistant Breast Cancer Xenografts.
Lai A; Kahraman M; Govek S; Nagasawa J; Bonnefous C; Julien J; Douglas K; Sensintaffar J; Lu N; Lee KJ; Aparicio A; Kaufman J; Qian J; Shao G; Prudente R; Moon MJ; Joseph JD; Darimont B; Brigham D; Grillot K; Heyman R; Rix PJ; Hager JH; Smith ND
J Med Chem; 2015 Jun; 58(12):4888-904. PubMed ID: 25879485
[TBL] [Abstract][Full Text] [Related]
12. A model of estrogen-related gene expression reveals non-linear effects in transcriptional response to tamoxifen.
Lebedeva G; Yamaguchi A; Langdon SP; Macleod K; Harrison DJ
BMC Syst Biol; 2012 Nov; 6():138. PubMed ID: 23134774
[TBL] [Abstract][Full Text] [Related]
13. Tamoxifen resistance in breast tumors is driven by growth factor receptor signaling with repression of classic estrogen receptor genomic function.
Massarweh S; Osborne CK; Creighton CJ; Qin L; Tsimelzon A; Huang S; Weiss H; Rimawi M; Schiff R
Cancer Res; 2008 Feb; 68(3):826-33. PubMed ID: 18245484
[TBL] [Abstract][Full Text] [Related]
14. Mechanisms of tamoxifen resistance: increased estrogen receptor-HER2/neu cross-talk in ER/HER2-positive breast cancer.
Shou J; Massarweh S; Osborne CK; Wakeling AE; Ali S; Weiss H; Schiff R
J Natl Cancer Inst; 2004 Jun; 96(12):926-35. PubMed ID: 15199112
[TBL] [Abstract][Full Text] [Related]
15. Resistance to tamoxifen-induced apoptosis is associated with direct interaction between Her2/neu and cell membrane estrogen receptor in breast cancer.
Chung YL; Sheu ML; Yang SC; Lin CH; Yen SH
Int J Cancer; 2002 Jan; 97(3):306-12. PubMed ID: 11774281
[TBL] [Abstract][Full Text] [Related]
16. A metastatic breast tumor cell line, GI-101A, is estrogen receptor positive and responsive to estrogen but resistant to tamoxifen.
Morrissey JJ; Raney S
Cell Biol Int; 1998; 22(6):413-9. PubMed ID: 10328849
[TBL] [Abstract][Full Text] [Related]
17. Dissemination of adjuvant multiagent chemotherapy and tamoxifen for breast cancer in the United States using estrogen receptor information: 1975-1999.
Mariotto AB; Feuer EJ; Harlan LC; Abrams J
J Natl Cancer Inst Monogr; 2006; (36):7-15. PubMed ID: 17032888
[TBL] [Abstract][Full Text] [Related]
18. Tamoxifen resistance and metastasis of human breast cancer cells were mediated by the membrane-associated estrogen receptor ER-α36 signaling in vitro.
Gu W; Dong N; Wang P; Shi C; Yang J; Wang J
Cell Biol Toxicol; 2017 Apr; 33(2):183-195. PubMed ID: 27837347
[TBL] [Abstract][Full Text] [Related]
19. NR4A1 Regulates Tamoxifen Resistance by Suppressing ERK Signaling in ER-Positive Breast Cancer.
Kim YC; Kim CY; Oh JH; Kim MH
Cells; 2021 Jun; 10(7):. PubMed ID: 34209871
[TBL] [Abstract][Full Text] [Related]
20. Roles of the ER-α36-EGFR/HER2 positive regulatory loops in tamoxifen resistance.
Yin L; Wang ZY
Steroids; 2016 Jul; 111():95-99. PubMed ID: 26884313
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]